Cargando…

Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry

The International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (NCT01374360) was initiated to optimize patient management by collecting data regarding disease burden, progression, and clinical outcomes. Herein, we report updated baseline demographics, clinical characteristics, disease burden d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schrezenmeier, Hubert, Röth, Alexander, Araten, David J., Kanakura, Yuzuru, Larratt, Loree, Shammo, Jamile M., Wilson, Amanda, Shayan, Gilda, Maciejewski, Jaroslaw P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316848/ https://www.ncbi.nlm.nih.gov/pubmed/32390114 http://dx.doi.org/10.1007/s00277-020-04052-z

Ejemplares similares

Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry
por: Dingli, David, et al.
Publicado: (2023)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
por: Lobry, Camille, et al.
Publicado: (2019)

A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ
por: Daly, R. Paola, et al.
Publicado: (2021)

Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Burns, Ethan, et al.
Publicado: (2019)

Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
por: Jang, Jun Ho, et al.
Publicado: (2016)

Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes
por: Höchsmann, Britta, et al.
Publicado: (2011)

Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry
por: Höchsmann, Britta, et al.
Publicado: (2023)

No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab
por: Alashkar, Ferras, et al.
Publicado: (2020)

Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data
por: Cella, David, et al.
Publicado: (2023)

New Insights in Abdominal Pain in Paroxysmal Nocturnal Hemoglobinuria (PNH): A MRI Study
por: De Cobelli, Francesco, et al.
Publicado: (2015)

Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients
por: Barcellini, Wilma, et al.
Publicado: (2018)

Bilateral Multiple Focal Choroidal Excavations in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Huang, Ping, et al.
Publicado: (2019)

The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Alashkar, Ferras, et al.
Publicado: (2018)

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
por: Shikdar, Sufana, et al.
Publicado: (2021)

P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
por: Peffault de Latour, Régis, et al.
Publicado: (2023)

S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

PB2040: LACTATE DEHYDROGENASE IS A PREDICTOR OF THROMBOEMBOLISM, AND THROMBOEMBOLISM IS A PREDICTOR OF DEATH, IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): RESULTS FROM A KOREAN PNH REGISTRY
por: Jang, Jun Ho, et al.
Publicado: (2023)

Popliteal artery thrombosis as a rare complication of paroxysmal nocturnal hemoglobinuria (PNH): A case report
por: Bhusal, Kiran, et al.
Publicado: (2021)

Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)—report on phases I and II
por: Groth, Martha, et al.
Publicado: (2016)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis
por: Sharma, Ruby, et al.
Publicado: (2015)

Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)
por: Weisshaar, Kimmo, et al.
Publicado: (2020)

Long Non-Coding RNA MALAT1 Contributed to the Proliferation of PNH Clone in Paroxysmal Nocturnal Hemoglobinuria Patients
por: Wang, Honglei, et al.
Publicado: (2021)

Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort
por: Choi, Chul Won, et al.
Publicado: (2017)

Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ(©))
por: Kaiser, Karen, et al.
Publicado: (2020)

Characteristics of Taiwanese patients of PNH in the international PNH registry
por: Chou, Wen-Chien, et al.
Publicado: (2016)

Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study
por: Chatzileontiadou, S., et al.
Publicado: (2023)

IMMUNE LYSIS OF NORMAL HUMAN AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELLS : III. THE MEMBRANE DEFECTS CAUSED BY COMPLEMENT LYSIS
por: Rosse, Wendell F., et al.
Publicado: (1966)

Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
por: Cheng, Wendy Y., et al.
Publicado: (2021)

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
por: Bodó, Imre, et al.
Publicado: (2023)

Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs
por: Bektas, Meryem, et al.
Publicado: (2020)

Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease
por: Bektas, Meryem, et al.
Publicado: (2020)

Paroxysmal nocturnal haemoglobinuria (PNH) manifesting on CT as a pathologic segment of small bowel
por: Zekria, David, et al.
Publicado: (2017)

Characteristics of paroxysmal nocturnal hemoglobinuria patients in Brazil: A retrospective administrative claims database analysis of PNH patients in Brazilian public healthcare system
por: Menosi Gualandro, Sandra Fatima, et al.
Publicado: (2023)

Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology
por: Bektas, Meryem, et al.
Publicado: (2020)

Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)—a report on phase III
por: Niedeggen, Cathrin, et al.
Publicado: (2019)

Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria—a pilot study (ePRO-AA-PNH)
por: Bänziger, Silas, et al.
Publicado: (2022)

PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Kulasekararaj, Austin, et al.
Publicado: (2023)

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS
por: Röth, Alexander, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ii56o5cf9hkcq4g4jfmt5ar2lm